Immune thrombocytopenia at the patient with a cystadenoma of the ovaries (а clinical case)
N. A. Pluzhnikova, 
V. E. Gruzdev,
T. E. Byalik,
E. A. Mustafina,
T. V. Davydova,
P. A. Zeinalova,
Z. S. Shikhabova
V. E. Gruzdev,
T. E. Byalik,
E. A. Mustafina,
T. V. Davydova,
P. A. Zeinalova,
Z. S. Shikhabova https://doi.org/10.17650/1818-8346-2020-15-1-51-58
Abstract
Immune thrombocytopenia is an immunosuppressed acquired disease characterized by low platelet levels in peripheral blood and an increased risk of bleeding. This pathology deserves special attention in cases of patients who are scheduled for surgery, which undoubtedly requires careful preparation of the patient for surgery and a complete laboratory analysis, including a thromboelastogram.
This article describes the clinical case of successful surgical treatment of a patient with immune thrombocytopenia.
About the Authors
N. A. Pluzhnikova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
V. E. Gruzdev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
T. E. Byalik
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991
Russian Federation
23 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991
E. A. Mustafina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
T. V. Davydova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
Russian Federation
23 Kashirskoe Shosse, Moscow 115478
P. A. Zeinalova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
23 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991
Russian Federation
23 Kashirskoe Shosse, Moscow 115478; Build. 2, 8 Trubetskaya St., Moscow 119991
Z. S. Shikhabova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Build. 2, 8 Trubetskaya St., Moscow 119991
Russian Federation
Build. 2, 8 Trubetskaya St., Moscow 119991
References
1. Neylon A.J., Saunders P.W., Howard M.R. et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a populationbased cohort of 245 patients. Br J Haematol 2003;122(6):966–74. DOI: 10.1046/j.13652141.2003.04547.x.
2. Terrell D.R., Beebe L.A., Vesely S.K. et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85(3):174–80. DOI: 10.1002/ajh.21616.
3. Lambert M.P., Gernsheimer T.B. Clinical updates in adult immune thrombocytopenia. Blood 2017;129(21):2829–35. DOI: 10.1182/blood201703754119.
4. McMillan R., Wang L., Tomer. A. et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004;103(4):1364–9. DOI: 10.1182/blood2003082672.
5. Zhao C., Li X., Zhang F. et al. Increased cytotoxic Tlymphocytemediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies. Haematologica 2008;93(9):1428–30. DOI: 10.3324/haematol.12889.
6. Kuwana M., Kaburaki J., Ikeda Y. Autoreactive T cells to platelet GPIIb–IIIa in immune thrombocytopenic purpura. Role inproduction of antiplatelet autoantibody. J Clin Invest 1998;102(7):1393–402. DOI: 10.1172/JCI4238.
7. Nugent D., McMillan R., Nichol J.L., Slichter S.J. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009;146(6):585–96. DOI: 10.1111/j.13652141.2009.07717.x.
8. Rodeghiero F., Stasi R., Gernsheimer T. et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113(11):2386–93. DOI: 10.1182/blood200807162503.
9. Neunert C., Lim W., Crowther M. et al. The American Society of Hematology 2011 evidencebased practice guideline for immune thrombocytopenia. Вlood 2011;117(16):4198–204. DOI: 10.1182/blood201008302984.
10. Provan D., Stasi R., Newland A.C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115(2):168–86. DOI: 10.1182/blood200906225565.
11. Cohen Y.C., Djuibegovic B., ShamaiLubovitz O., Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med 2000;160(11):1630–8. DOI: 10.1001/archinte.160.11.1630.
12. Arnold D.M., Nazy I., Clare R. et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv 2017;1(25):2414–20. DOI: 10.1182/bloodadvances.2017010942.
13. Altintas A., Ozel A., Okur N. et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis,2007;24(2):163–8. DOI: 10.1007/s112390070031y.
14. MelboucyBelkhir S., Khellaf M., Augier A. et al. Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: A study of 27 cases. Am J Hematol 2016;91(12):E499–501. DOI: 10.1002/ajh.24529.
15. GrimaldiBensouda L., Nordon C., Michel M. et al. Group for the PGRxITP Study. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica 2016;101(9):1039–45. DOI: 10.3324/haematol.2016.146373.
16. Segal J.B., Powe N.R. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost 2006;4(11):2377–83. DOI: 10.1111/j.15387836.2006.02147.x.
17. Gulidova O.V. If surgery is planned. Available at: http:/www.unimedao.ru/articles/6826/9673/item/34. (In Russ.).
18. Yarets Yu.I. Thromboelastography: basic parameters, the interpretation of results. Gomel: RSC RMHE, 2018. 26 p. (In Russ.).
19. Cuker A., Cines D.B., Neunert C.E. Controversies in the treatment of immune thrombocytopenia. Curr Opin Hematol 2016;23(5):479–85. DOI: 10.1097/MOH.0000000000000270.
20. Din B., Wang X., Shi Y., Li Y. Longterm effect of highdose dexamethasone with or without lowdose dexamethasone maintenance in untreated immune thrombocytopenia. Acta Haematol 2015;133(1):2124–8. DOI: 10.1159/000362529.
21. Matschke J., MüllerBeissenhirtz H., Novotny J. et al. A randomized trial of daily prednisone versus pulsed dexamethasone in treatmentnaive adult patients with immune thrombocytopenia: EIS 2002 Study. Acta Haematol 2016;136(2):101–7. DOI: 10.1159/000445420.
22. Kojouri K., Vesely S.K., Terrell D.R. et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess longterm platelet count responses, prediction of response, and surgical complications. Blood 2004;104(9):2623–34. DOI: 10.1182/blood2004031168.
23. Thai L.H., Mahevas M., RoudotThoraval F. et al. Longterm complications after splenectomy in adult chronic immune thrombocytopenia with a minimum follow up of 10 years. First results from a singlecenter casecontrol study in 140 patients with primary ITP. Program and abstracts of the 56th Annual Meeting of the American Society of Hematology. December 6–9, 2014. San Francisco, California. Abstract 232.
24. GuanY., Wang S., Xue F. et al. Longterm results of splenectomy in adult chronic immune thrombocytopenia. Eur J Haematol 2017;98(3):235–41. DOI: 10.1111/ejh.12821.
25. Cooper N., Stasi R., CunninghamRundles S. et al. The efficacy and safety of Bcell depletion with antiCD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004;125(2):232–9. DOI: 10.1111/j.13652141.2004.04889.x.
26. Zaja F., Baccarani M., Mazza P. et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010;155(14):2755–62. DOI: 10.1182/blood200907229815.
27. Patel V.L., Mahevas M., Lee S.Y. et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119(25):5989–95. DOI: 10.1182/blood201111393975.
28. Marangon M., Vianelli N., Palandri F. et al. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of longterm response. Eur J Haematol 2017;98(4):371–7. DOI: 10.1111/ejh.12839.
29. Mazza P., Minoia C., Melpignano A. et al. The use of thrombopoietinreceptor agonists (TPORAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol 2016;95(2):239–44. DOI: 10.1007/s002770152556z.
30. GonzálezLópez T.J., AlvarezRomán M.T., Pascual C. et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice. Eur J Haematol 2016;97(3):297–302. DOI: 10.1111/ejh.12725.
31. Saleh M.N., Bussel J.B., Cheng G. et al. EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the longterm, openlabel EXTEND study. Blood 2013;121(3):537–45. DOI: 10.1182/blood201204425512.
32. Nagalla S. Platelet response to avatrombopag in patients with chronic immue thrombocytopenia. ASH 2019. Abstract 1071.
33. Panzer S., Rieger M., Vormittag R., Eichelberger B. et al. Platelet function to estimate the bleeding risk in autoimmune thrombocytopenia. Eur J Clin Invest 2007;37(10):814–9. DOI: 10.1111/j.13652362.2007. 01855.x.
Review
For citations:
Pluzhnikova N.A., Gruzdev V.E., Byalik T.E., Mustafina E.A., Davydova T.V., Zeinalova P.A., Shikhabova Z.S. Immune thrombocytopenia at the patient with a cystadenoma of the ovaries (а clinical case). Oncohematology. 2020;15(1):51-58. (In Russ.) https://doi.org/10.17650/1818-8346-2020-15-1-51-58
Views:
9571
Email this article 